HPC
NTLA icon

HM Payson & Co’s Intellia Therapeutics NTLA Stock Holding History

HM Payson & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1K Hold
65
– – ﹤0.01% 1085
2026
Q1 		$834 Hold
65
– – ﹤0.01% 1081
2025
Q4 		$585 Hold
65
– – ﹤0.01% 1119
2025
Q3 		$1.12K Hold
65
– – ﹤0.01% 1045
2025
Q2 		$610 Hold
65
– – ﹤0.01% 966
2025
Q1 		$463 Hold
65
– – ﹤0.01% 1015
2024
Q4 		$758 Hold
65
– – ﹤0.01% 1003
2024
Q3 		$1.34K Hold
65
– – ﹤0.01% 1004
2024
Q2 		$1.46K Hold
65
– – ﹤0.01% 939
2024
Q1 		$1.79K Hold
65
– – ﹤0.01% 905
2023
Q4 		$1.98K Hold
65
– – ﹤0.01% 904
2023
Q3 		$2.06K Hold
65
– – ﹤0.01% 930
2023
Q2 		$2.65K Hold
65
– – ﹤0.01% 898
2023
Q1 		$2.42K Hold
65
– – ﹤0.01% 910
2022
Q4 		$2.27K Hold
65
– – ﹤0.01% 849
2022
Q3 		$4K Hold
65
– – ﹤0.01% 869
2022
Q2 		$3K Hold
65
– – ﹤0.01% 931
2022
Q1 		$5K Hold
65
– – ﹤0.01% 915
2021
Q4 		$8K Hold
65
– – ﹤0.01% 898
2021
Q3 		$9K Buy
+65
New +$9.84K ﹤0.01% 846

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

HM Payson & Co's NTLA Position: Q2 2026 in Review

HM Payson & Co held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 65 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1085.

HM Payson & Co first reported a position in NTLA in Q3 2021 and has held it in 20 quarters since. The position peaked at $9K in Q3 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • HM Payson & Co held 65 shares of Intellia Therapeutics worth $1.1K as of Q2 2026.
  • HM Payson & Co left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #1085 holding.
  • HM Payson & Co first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • HM Payson & Co's Intellia Therapeutics position peaked at $9K in Q3 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.